Skip to main navigation Skip to search Skip to main content

Design on a Rational Basis of High-Affinity Peptides Inhibiting the Histone Chaperone ASF1

  • May Bakail
  • , Albane Gaubert
  • , Jessica Andreani
  • , Gwenaëlle Moal
  • , Guillaume Pinna
  • , Ekaterina Boyarchuk
  • , Marie Cécile Gaillard
  • , Regis Courbeyrette
  • , Carl Mann
  • , Jean Yves Thuret
  • , Bérengère Guichard
  • , Brice Murciano
  • , Nicolas Richet
  • , Adeline Poitou
  • , Claire Frederic
  • , Marie Hélène Le Du
  • , Morgane Agez
  • , Caroline Roelants
  • , Zachary A. Gurard-Levin
  • , Geneviève Almouzni
  • Nadia Cherradi, Raphael Guerois, Françoise Ochsenbein
  • Institute Joliot
  • Institut Pierre Simon Laplace, CNRS and CEA
  • Université Paris-Saclay
  • CNRS UMR218
  • Centre national de la recherche scientifique
  • Institut National de la Santé et de la Recherche Médicale
  • INSERM U869
  • Commissariat à l'Energie Atomique
  • Univ. Joseph Fourier-Grenoble 1
  • Unité Mixte de Recherche-S1036
  • LTHE (UMR 5564 CNRS/IRD/Université de Grenoble)

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Anti-silencing function 1 (ASF1) is a conserved H3-H4 histone chaperone involved in histone dynamics during replication, transcription, and DNA repair. Overexpressed in proliferating tissues including many tumors, ASF1 has emerged as a promising therapeutic target. Here, we combine structural, computational, and biochemical approaches to design peptides that inhibit the ASF1-histone interaction. Starting from the structure of the human ASF1-histone complex, we developed a rational design strategy combining epitope tethering and optimization of interface contacts to identify a potent peptide inhibitor with a dissociation constant of 3 nM. When introduced into cultured cells, the inhibitors impair cell proliferation, perturb cell-cycle progression, and reduce cell migration and invasion in a manner commensurate with their affinity for ASF1. Finally, we find that direct injection of the most potent ASF1 peptide inhibitor in mouse allografts reduces tumor growth. Our results open new avenues to use ASF1 inhibitors as promising leads for cancer therapy. Bakail et al. developed a strategy for designing peptide inhibitors of protein-protein interactions, based on tethering binding epitopes to increase their affinity and specificity. This strategy was applied to the inhibition of the histone chaperone ASF1, which is essential for the early steps of chromatin assembly and represents a novel target in cancer research.

Original languageEnglish
Pages (from-to)1573-1585.e10
JournalCell Chemical Biology
Volume26
Issue number11
DOIs
Publication statusPublished - 21 Nov 2019
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cancer
  • Cell Penetrating Peptide
  • Chromatin
  • Drug Design
  • Epigenetics
  • Peptide Inhibitor
  • Protein Binding
  • Protein-Protein Interaction
  • Rosetta Design
  • X-Ray Crystallography

Fingerprint

Dive into the research topics of 'Design on a Rational Basis of High-Affinity Peptides Inhibiting the Histone Chaperone ASF1'. Together they form a unique fingerprint.

Cite this